DBV Technologies(US:DBVT) Newsfilterยท2024-05-30 20:30Core Viewpoint - DBV Technologies is actively participating in the EAACI 2024 Congress to present its research on Viaskin Peanut, focusing on its potential to treat peanut allergies in young children and the importance of understanding accidental peanut consumption during treatment [1][2][3]. Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company dedicated to developing treatment options for food allergies and other immunologic conditions, particularly through its proprietary Viaskin technology [7]. - The company aims to address significant unmet medical needs in food allergies, which affect millions, including young children [7]. Upcoming Events - DBV Technologies will present a flash talk on data from its EPITOPE Phase 3 study regarding accidental peanut consumption in toddlers aged 1 to 3 years during the EAACI Congress [2][5]. - The company will host a symposium titled "Epicutaneous Route: An Innovative Potential Approach to Food Immunotherapy," featuring expert lectures on the clinical applications of epicutaneous immunotherapy [3][6]. Research Focus - The company emphasizes the importance of establishing long-term safety and clinical data for Viaskin Peanut, particularly in pediatric populations, to understand the implications of accidental allergen exposure [3]. - DBV Technologies is conducting ongoing clinical trials for Viaskin Peanut in peanut-allergic toddlers and children, aiming to modify the immune response to allergens through epicutaneous immunotherapy [7]. Exhibition Details - DBV will have an exhibit booth (F10) at the EAACI Congress, where attendees can learn more about its ongoing clinical trials and the Viaskin technology [4].